{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:40:29Z","timestamp":1792276829343,"version":"4.4.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:00:00Z","timestamp":1792195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2025ZD0545600"],"award-info":[{"award-number":["2025ZD0545600"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"DOI":"10.1007\/s10555-026-10385-4","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T12:07:14Z","timestamp":1792238834000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Histotype and molecular subtype integration in epithelial ovarian cancer: implications for targeted treatment"],"prefix":"10.1007","volume":"45","author":[{"given":"Shuyi","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,17]]},"reference":[{"key":"10385_CR1","doi-asserted-by":"publisher","first-page":"e70090","DOI":"10.3322\/caac.70090","volume":"76","author":"H Sung","year":"2026","unstructured":"Sung, H., et al. (2026). Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA: A Cancer Journal for Clinicians, 76, e70090. https:\/\/doi.org\/10.3322\/caac.70090","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10385_CR2","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Braunstein, M., & Oza, A. M. (2019). Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA: A Cancer Journal for Clinicians, 69, 280\u2013304. https:\/\/doi.org\/10.3322\/caac.21559","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10385_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","volume":"111","author":"LC Peres","year":"2019","unstructured":"Peres, L. C., et al. (2019). Invasive epithelial ovarian cancer survival by histotype and disease stage. J Natl Cancer Inst, 111, 60\u201368. https:\/\/doi.org\/10.1093\/jnci\/djy071","journal-title":"J Natl Cancer Inst"},{"key":"10385_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre, L. A., et al. (2018). Ovarian cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 284\u2013296. https:\/\/doi.org\/10.3322\/caac.21456","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10385_CR5","doi-asserted-by":"publisher","first-page":"216057","DOI":"10.1016\/j.canlet.2023.216057","volume":"555","author":"RL Hollis","year":"2023","unstructured":"Hollis, R. L. (2023). Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Letters, 555, 216057. https:\/\/doi.org\/10.1016\/j.canlet.2023.216057","journal-title":"Cancer Letters"},{"key":"10385_CR6","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3322\/caac.70008","volume":"75","author":"P Kordowitzki","year":"2025","unstructured":"Kordowitzki, P., et al. (2025). Transforming treatment paradigms: Focus on personalized medicine for high-grade serous ovarian cancer. CA: A Cancer Journal for Clinicians, 75, 436\u2013460. https:\/\/doi.org\/10.3322\/caac.70008","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"10385_CR7","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1158\/0008-5472.Can-11-3911","volume":"72","author":"EM Berns","year":"2012","unstructured":"Berns, E. M., & Bowtell, D. D. (2012). The changing view of high-grade serous ovarian cancer. Cancer Res, 72, 2701\u20132704. https:\/\/doi.org\/10.1158\/0008-5472.Can-11-3911","journal-title":"Cancer Res"},{"key":"10385_CR8","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell, D. D., et al. (2015). Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nature Reviews. Cancer, 15, 668\u2013679. https:\/\/doi.org\/10.1038\/nrc4019","journal-title":"Nature Reviews. Cancer"},{"key":"10385_CR9","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Integrated genomic analyses of ovarian carcinoma","year":"2011","unstructured":"Integrated genomic analyses of ovarian carcinoma. (2011). Nature, 474, 609\u2013615. https:\/\/doi.org\/10.1038\/nature10166","journal-title":"Nature"},{"key":"10385_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-021-01424-5","volume":"20","author":"AL Drumond-Bock","year":"2021","unstructured":"Drumond-Bock, A. L., & Bieniasz, M. (2021). The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis. Mol Cancer, 20, 145. https:\/\/doi.org\/10.1186\/s12943-021-01424-5","journal-title":"Mol Cancer"},{"key":"10385_CR11","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.3802\/jgo.2025.36.e74","volume":"36","author":"YY Leung","year":"2025","unstructured":"Leung, Y. Y., et al. (2025). FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: Unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma. Journal of Gynecologic Oncology, 36, e74. https:\/\/doi.org\/10.3802\/jgo.2025.36.e74","journal-title":"Journal of Gynecologic Oncology"},{"key":"10385_CR12","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1158\/1078-0432.Ccr-21-4183","volume":"28","author":"B Manning-Geist","year":"2022","unstructured":"Manning-Geist, B., et al. (2022). MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clinical Cancer Research, 28, 4456\u20134465. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-4183","journal-title":"Clinical Cancer Research"},{"issue":"Suppl 1","key":"10385_CR13","doi-asserted-by":"publisher","first-page":"i16","DOI":"10.1093\/annonc\/mdw089","volume":"27","author":"A Malpica","year":"2016","unstructured":"Malpica, A., & Wong, K. K. (2016). The molecular pathology of ovarian serous borderline tumors. Annals of Oncology, 27(Suppl 1), i16\u2013i19. https:\/\/doi.org\/10.1093\/annonc\/mdw089","journal-title":"Annals of Oncology"},{"key":"10385_CR14","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.ygyno.2021.11.019","volume":"165","author":"DM Gershenson","year":"2022","unstructured":"Gershenson, D. M., et al. (2022). The genomic landscape of low-grade serous ovarian\/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol, 165, 560\u2013567. https:\/\/doi.org\/10.1016\/j.ygyno.2021.11.019","journal-title":"Gynecol Oncol"},{"key":"10385_CR15","doi-asserted-by":"publisher","first-page":"102497","DOI":"10.1016\/j.ctrv.2022.102497","volume":"112","author":"TA Zwimpfer","year":"2023","unstructured":"Zwimpfer, T. A., et al. (2023). Low grade serous ovarian cancer - A rare disease with increasing therapeutic options. Cancer Treatment Reviews, 112, 102497. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102497","journal-title":"Cancer Treatment Reviews"},{"key":"10385_CR16","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","volume":"363","author":"KC Wiegand","year":"2010","unstructured":"Wiegand, K. C., et al. (2010). ARID1A mutations in endometriosis-associated ovarian carcinomas. New England Journal of Medicine, 363, 1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1008433","journal-title":"New England Journal of Medicine"},{"key":"10385_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1126\/science.1196333","volume":"330","author":"S Jones","year":"2010","unstructured":"Jones, S., et al. (2010). Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science, 330, 228\u2013231. https:\/\/doi.org\/10.1126\/science.1196333","journal-title":"Science"},{"key":"10385_CR18","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.2353\/ajpath.2009.081000","volume":"174","author":"KT Kuo","year":"2009","unstructured":"Kuo, K. T., et al. (2009). Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. American Journal of Pathology, 174, 1597\u20131601. https:\/\/doi.org\/10.2353\/ajpath.2009.081000","journal-title":"American Journal of Pathology"},{"key":"10385_CR19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/ijgc-2022-003658","volume":"33","author":"D Nugawela","year":"2023","unstructured":"Nugawela, D., & Gorringe, K. L. (2023). Targeted therapy for mucinous ovarian carcinoma: Evidence from clinical trials. International Journal of Gynecological Cancer, 33, 102\u2013108. https:\/\/doi.org\/10.1136\/ijgc-2022-003658","journal-title":"International Journal of Gynecological Cancer"},{"key":"10385_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ygyno.2019.03.256","volume":"153","author":"M Gore","year":"2019","unstructured":"Gore, M., et al. (2019). An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC\/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol, 153, 541\u2013548. https:\/\/doi.org\/10.1016\/j.ygyno.2019.03.256","journal-title":"Gynecol Oncol"},{"key":"10385_CR21","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang, S., et al. (2025). Generic diagramming platform (GDP): A comprehensive database of high-quality biomedical graphics. Nucleic Acids Research, 53, D1670-d1676. https:\/\/doi.org\/10.1093\/nar\/gkae973","journal-title":"Nucleic Acids Research"},{"key":"10385_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.6004\/jnccn.2024.0052","volume":"22","author":"J Liu","year":"2024","unstructured":"Liu, J., et al. (2024). NCCN Guidelines\u00ae Insights: Ovarian Cancer\/Fallopian tube cancer\/primary peritoneal cancer, version 3.2024: featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network, 22, 512\u2013519. https:\/\/doi.org\/10.6004\/jnccn.2024.0052","journal-title":"Journal of the National Comprehensive Cancer Network"},{"key":"10385_CR23","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/s0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021). Breast cancer. Lancet, 397, 1750\u20131769. https:\/\/doi.org\/10.1016\/s0140-6736(20)32381-3","journal-title":"Lancet"},{"key":"10385_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/jco.21.01874","volume":"40","author":"DM O'Malley","year":"2022","unstructured":"O\u2019Malley, D. M., et al. (2022). Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol, 40, 752\u2013761. https:\/\/doi.org\/10.1200\/jco.21.01874","journal-title":"J Clin Oncol"},{"key":"10385_CR25","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1038\/s41591-024-03250-w","volume":"30","author":"PGM de Gooyer","year":"2024","unstructured":"de Gooyer, P. G. M., et al. (2024). Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nat Med, 30, 3284\u20133290. https:\/\/doi.org\/10.1038\/s41591-024-03250-w","journal-title":"Nat Med"},{"key":"10385_CR26","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","volume":"381","author":"S Kopetz","year":"2019","unstructured":"Kopetz, S., et al. (2019). Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med, 381, 1632\u20131643. https:\/\/doi.org\/10.1056\/NEJMoa1908075","journal-title":"N Engl J Med"},{"key":"10385_CR27","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1200\/jco.2017.76.9331","volume":"36","author":"N Kornblum","year":"2018","unstructured":"Kornblum, N., et al. (2018). Randomized phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy: Results of PrE0102. Journal of Clinical Oncology, 36, 1556\u20131563. https:\/\/doi.org\/10.1200\/jco.2017.76.9331","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR28","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41418-022-00962-9","volume":"29","author":"Z Wang","year":"2022","unstructured":"Wang, Z., Strasser, A., & Kelly, G. L. (2022). Should mutant TP53 be targeted for cancer therapy? Cell Death and Differentiation, 29, 911\u2013920. https:\/\/doi.org\/10.1038\/s41418-022-00962-9","journal-title":"Cell Death and Differentiation"},{"key":"10385_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/s1470-2045(03)01139-2","volume":"4","author":"AG Zeimet","year":"2003","unstructured":"Zeimet, A. G., & Marth, C. (2003). Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol, 4, 415\u2013422. https:\/\/doi.org\/10.1016\/s1470-2045(03)01139-2","journal-title":"Lancet Oncol"},{"key":"10385_CR30","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","volume":"15","author":"K Sabapathy","year":"2018","unstructured":"Sabapathy, K., & Lane, D. P. (2018). Therapeutic targeting of p53: All mutants are equal, but some mutants are more equal than others. Nature Reviews Clinical Oncology, 15, 13\u201330. https:\/\/doi.org\/10.1038\/nrclinonc.2017.151","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10385_CR31","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/jco.20.02341","volume":"39","author":"DA Sallman","year":"2021","unstructured":"Sallman, D. A., et al. (2021). Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes. J Clin Oncol, 39, 1584\u20131594. https:\/\/doi.org\/10.1200\/jco.20.02341","journal-title":"J Clin Oncol"},{"key":"10385_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-024-00579-9","volume":"12","author":"JE Zawacka","year":"2024","unstructured":"Zawacka, J. E. (2024). p53 biology and reactivation for improved therapy in MDS and AML. Biomark Res, 12, 34. https:\/\/doi.org\/10.1186\/s40364-024-00579-9","journal-title":"Biomark Res"},{"key":"10385_CR33","unstructured":"Therapeutics, A. Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS), <https:\/\/aprea.gcs-web.com\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3> (2020)."},{"key":"10385_CR34","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1056\/NEJMoa2508820","volume":"394","author":"EE Dumbrava","year":"2026","unstructured":"Dumbrava, E. E., et al. (2026). Phase 1 Study of Rezatapopt, a p53 Reactivator, in TP53 Y220C-Mutated Tumors. N Engl J Med, 394, 872\u2013883. https:\/\/doi.org\/10.1056\/NEJMoa2508820","journal-title":"N Engl J Med"},{"key":"10385_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1200\/JCO.2026.44.19_suppl.201","volume":"44","author":"TJ Tan","year":"2026","unstructured":"Tan, T. J., et al. (2026). Pivotal PYNNACLE phase 2 trial of rezatapopt in heavily pre-treated, advanced solid tumors with a TP53 Y220C mutation: Initial ovarian cancer analysis. Journal of Clinical Oncology, 44, 201\u2013201. https:\/\/doi.org\/10.1200\/JCO.2026.44.19_suppl.201","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR36","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/nature08467","volume":"461","author":"SP Jackson","year":"2009","unstructured":"Jackson, S. P., & Bartek, J. (2009). The DNA-damage response in human biology and disease. Nature, 461, 1071\u20131078. https:\/\/doi.org\/10.1038\/nature08467","journal-title":"Nature"},{"key":"10385_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","volume":"16","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019). State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol, 16, 81\u2013104. https:\/\/doi.org\/10.1038\/s41571-018-0114-z","journal-title":"Nat Rev Clin Oncol"},{"key":"10385_CR38","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"10385_CR39","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nature07943","volume":"458","author":"MR Stratton","year":"2009","unstructured":"Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009). The cancer genome. Nature, 458, 719\u2013724. https:\/\/doi.org\/10.1038\/nature07943","journal-title":"Nature"},{"key":"10385_CR40","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/nrm2858","volume":"11","author":"S Negrini","year":"2010","unstructured":"Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010). Genomic instability\u2013an evolving hallmark of cancer. Nature Reviews Molecular Cell Biology, 11, 220\u2013228. https:\/\/doi.org\/10.1038\/nrm2858","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10385_CR41","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","volume":"19","author":"A Huang","year":"2020","unstructured":"Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. (2020). Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov, 19, 23\u201338. https:\/\/doi.org\/10.1038\/s41573-019-0046-z","journal-title":"Nat Rev Drug Discov"},{"key":"10385_CR42","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917\u2013921. https:\/\/doi.org\/10.1038\/nature03445","journal-title":"Nature"},{"key":"10385_CR43","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E., et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913\u2013917. https:\/\/doi.org\/10.1038\/nature03443","journal-title":"Nature"},{"key":"10385_CR44","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.Cd-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D\u2019Andrea, A. D. (2015). Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer. Cancer Discov, 5, 1137\u20131154. https:\/\/doi.org\/10.1158\/2159-8290.Cd-15-0714","journal-title":"Cancer Discov"},{"key":"10385_CR45","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13045-022-01360-x","volume":"15","author":"S Li","year":"2022","unstructured":"Li, S., et al. (2022). The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment. J Hematol Oncol, 15, 147. https:\/\/doi.org\/10.1186\/s13045-022-01360-x","journal-title":"J Hematol Oncol"},{"key":"10385_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-med-082523-083843","volume":"76","author":"A Ghanem","year":"2025","unstructured":"Ghanem, A., & Domchek, S. M. (2025). New therapeutic options for BRCA mutant patients. Annual Review of Medicine, 76, 175\u2013187. https:\/\/doi.org\/10.1146\/annurev-med-082523-083843","journal-title":"Annual Review of Medicine"},{"key":"10385_CR47","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/s1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore, K. N., et al. (2019). Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncology, 20, 636\u2013648. https:\/\/doi.org\/10.1016\/s1470-2045(19)30029-4","journal-title":"Lancet Oncology"},{"key":"10385_CR48","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","volume":"12","author":"EM Swisher","year":"2021","unstructured":"Swisher, E. M., et al. (2021). Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat Commun, 12, 2487. https:\/\/doi.org\/10.1038\/s41467-021-22582-6","journal-title":"Nat Commun"},{"key":"10385_CR49","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K., et al. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med, 379, 2495\u20132505. https:\/\/doi.org\/10.1056\/NEJMoa1810858","journal-title":"N Engl J Med"},{"key":"10385_CR50","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1016\/s1470-2045(21)00531-3","volume":"22","author":"S Banerjee","year":"2021","unstructured":"Banerjee, S., et al. (2021). Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, 22, 1721\u20131731. https:\/\/doi.org\/10.1016\/s1470-2045(21)00531-3","journal-title":"Lancet Oncology"},{"key":"10385_CR51","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/s1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E., et al. (2017). Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, 18, 1274\u20131284. https:\/\/doi.org\/10.1016\/s1470-2045(17)30469-2","journal-title":"Lancet Oncology"},{"key":"10385_CR52","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/s1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda, A., et al. (2021). Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncology, 22, 620\u2013631. https:\/\/doi.org\/10.1016\/s1470-2045(21)00073-5","journal-title":"Lancet Oncology"},{"key":"10385_CR53","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A., et al. (2019). Niraparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 381, 2391\u20132402. https:\/\/doi.org\/10.1056\/NEJMoa1910962","journal-title":"New England Journal of Medicine"},{"key":"10385_CR54","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I., et al. (2019). Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med, 381, 2416\u20132428. https:\/\/doi.org\/10.1056\/NEJMoa1911361","journal-title":"N Engl J Med"},{"key":"10385_CR55","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R., et al. (2016). Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med, 375, 2154\u20132164. https:\/\/doi.org\/10.1056\/NEJMoa1611310","journal-title":"N Engl J Med"},{"key":"10385_CR56","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/jco.18.02238","volume":"37","author":"JM Del Campo","year":"2019","unstructured":"Del Campo, J. M., et al. (2019). Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA Trial. J Clin Oncol, 37, 2968\u20132973. https:\/\/doi.org\/10.1200\/jco.18.02238","journal-title":"J Clin Oncol"},{"key":"10385_CR57","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"XH Wu","year":"2021","unstructured":"Wu, X. H., et al. (2021). Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial(\u2606). Ann Oncol, 32, 512\u2013521. https:\/\/doi.org\/10.1016\/j.annonc.2020.12.018","journal-title":"Ann Oncol"},{"key":"10385_CR58","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/s0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L., et al. (2017). Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 390, 1949\u20131961. https:\/\/doi.org\/10.1016\/s0140-6736(17)32440-6","journal-title":"Lancet"},{"key":"10385_CR59","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/s1470-2045(24)00674-0","volume":"26","author":"AM Oza","year":"2025","unstructured":"Oza, A. M., et al. (2025). Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial. Lancet Oncol, 26, 249\u2013264. https:\/\/doi.org\/10.1016\/s1470-2045(24)00674-0","journal-title":"Lancet Oncol"},{"key":"10385_CR60","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/s1470-2045(22)00122-x","volume":"23","author":"R Kristeleit","year":"2022","unstructured":"Kristeleit, R., et al. (2022). Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol, 23, 465\u2013478. https:\/\/doi.org\/10.1016\/s1470-2045(22)00122-x","journal-title":"Lancet Oncol"},{"key":"10385_CR61","doi-asserted-by":"publisher","first-page":"3952","DOI":"10.1200\/jco.22.01003","volume":"40","author":"BJ Monk","year":"2022","unstructured":"Monk, B. J., et al. (2022). A randomized, Phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). Journal of Clinical Oncology, 40, 3952\u20133964. https:\/\/doi.org\/10.1200\/jco.22.01003","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR62","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1038\/s41591-024-03003-9","volume":"30","author":"X Wu","year":"2024","unstructured":"Wu, X., et al. (2024). Senaparib as first-line maintenance therapy in advanced ovarian cancer: A randomized phase 3 trial. Nature Medicine, 30, 1612\u20131621. https:\/\/doi.org\/10.1038\/s41591-024-03003-9","journal-title":"Nature Medicine"},{"key":"10385_CR63","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ygyno.2021.12.003","volume":"164","author":"EM Swisher","year":"2022","unstructured":"Swisher, E. M., et al. (2022). Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA\/GOG-3005 study. Gynecologic Oncology, 164, 245\u2013253. https:\/\/doi.org\/10.1016\/j.ygyno.2021.12.003","journal-title":"Gynecologic Oncology"},{"key":"10385_CR64","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/s1470-2045(18)30905-7","volume":"20","author":"PA Konstantinopoulos","year":"2019","unstructured":"Konstantinopoulos, P. A., et al. (2019). Olaparib and \u03b1-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: A dose-escalation and dose-expansion phase 1b trial. Lancet Oncology, 20, 570\u2013580. https:\/\/doi.org\/10.1016\/s1470-2045(18)30905-7","journal-title":"Lancet Oncology"},{"key":"10385_CR65","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1200\/jco-25-00225","volume":"43","author":"PA Konstantinopoulos","year":"2025","unstructured":"Konstantinopoulos, P. A., et al. (2025). Primary analysis of EPIK-O\/ENGOT-ov61: Alpelisib plus olaparib versus chemotherapy in platinum-resistant or platinum-refractory high-grade serous ovarian cancer without BRCA mutation. Journal of Clinical Oncology, 43, 2908\u20132917. https:\/\/doi.org\/10.1200\/jco-25-00225","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR66","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1158\/1078-0432.Ccr-21-1279","volume":"27","author":"KT Do","year":"2021","unstructured":"Do, K. T., et al. (2021). Phase 1 combination study of the CHK1 inhibitor prexasertib and the PARP inhibitor olaparib in high-grade serous ovarian cancer and other solid tumors. Clinical Cancer Research, 27, 4710\u20134716. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1279","journal-title":"Clinical Cancer Research"},{"key":"10385_CR67","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1078-0432.Ccr-23-2249","volume":"30","author":"Y Drew","year":"2024","unstructured":"Drew, Y., et al. (2024). Olaparib plus Durvalumab, with or without bevacizumab, as treatment in PARP inhibitor-na\u00efve platinum-sensitive relapsed ovarian cancer: a phase II multi-cohort study. Clinical Cancer Research, 30, 50\u201362. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2249","journal-title":"Clinical Cancer Research"},{"key":"10385_CR68","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1200\/jco.24.00683","volume":"42","author":"JM Lee","year":"2024","unstructured":"Lee, J. M., et al. (2024). Cediranib and olaparib combination compared with cediranib or olaparib alone, or chemotherapy in platinum-resistant or primary platinum-refractory ovarian cancer: NRG-GY005. Journal of Clinical Oncology, 42, 4305\u20134316. https:\/\/doi.org\/10.1200\/jco.24.00683","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR69","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.annonc.2025.11.020","volume":"37","author":"P Harter","year":"2026","unstructured":"Harter, P., et al. (2026). Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. Annals of Oncology, 37, 503\u2013520. https:\/\/doi.org\/10.1016\/j.annonc.2025.11.020","journal-title":"Annals of Oncology"},{"key":"10385_CR70","doi-asserted-by":"publisher","first-page":"TPS5603","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS5603","volume":"37","author":"I Vergote","year":"2019","unstructured":"Vergote, I., et al. (2019). ENGOT-OV43\/KEYLYNK-001: A phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer. Journal of Clinical Oncology, 37, TPS5603\u2013TPS5603. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS5603","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR71","doi-asserted-by":"publisher","first-page":"LBA5506","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5506","volume":"43","author":"A-C Hardy-Bessard","year":"2025","unstructured":"Hardy-Bessard, A.-C., et al. (2025). FIRST\/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC). Journal of Clinical Oncology, 43, LBA5506\u2013LBA5506. https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA5506","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR72","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-018-0915-9","volume":"17","author":"B Donati","year":"2018","unstructured":"Donati, B., Lorenzini, E., & Ciarrocchi, A. (2018). BRD4 and Cancer: going beyond transcriptional regulation. Mol Cancer, 17, 164. https:\/\/doi.org\/10.1186\/s12943-018-0915-9","journal-title":"Mol Cancer"},{"key":"10385_CR73","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.celrep.2017.12.078","volume":"22","author":"X Li","year":"2018","unstructured":"Li, X., et al. (2018). BRD4 promotes DNA repair and mediates the formation of TMPRSS2-ERG gene rearrangements in prostate cancer. Cell Reports, 22, 796\u2013808. https:\/\/doi.org\/10.1016\/j.celrep.2017.12.078","journal-title":"Cell Reports"},{"key":"10385_CR74","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2018.01.019","volume":"33","author":"C Sun","year":"2018","unstructured":"Sun, C., et al. (2018). BRD4 inhibition is synthetic lethal with PARP inhibitors through the induction of homologous recombination deficiency. Cancer Cell, 33, 401-416.e408. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.019","journal-title":"Cancer Cell"},{"key":"10385_CR75","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/1535-7163.Mct-23-0065","volume":"22","author":"EP Hamilton","year":"2023","unstructured":"Hamilton, E. P., et al. (2023). First-in-human study of AZD5153, a small-molecule inhibitor of bromodomain protein 4, in patients with relapsed\/refractory malignant solid tumors and lymphoma. Mol Cancer Ther, 22, 1154\u20131165. https:\/\/doi.org\/10.1158\/1535-7163.Mct-23-0065","journal-title":"Mol Cancer Ther"},{"key":"10385_CR76","doi-asserted-by":"crossref","unstructured":"Frenel, J.-S., et al. (2026). Rezatapopt, a selective p53 reactivator, in advanced or metastatic solid tumours with a TP53 Y220C mutation: Interim efficacy results from patients with ovarian cancer in the Phase 2 PYNNACLE trial. https:\/\/www.pynnaclestudy.com\/file.cfm\/19\/docs\/ma-586-0158_esgo_2026_phase_2_interim_analaysis_ovarian_poster_feb2026_approved.pdf","DOI":"10.1016\/j.ijgc.2025.103070"},{"key":"10385_CR77","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/jco.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis, U. A., et al. (2023). Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. Journal of Clinical Oncology, 41, 2436\u20132445. https:\/\/doi.org\/10.1200\/jco.22.01900","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR78","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore, K. N., et al. (2023). Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. New England Journal of Medicine, 389, 2162\u20132174. https:\/\/doi.org\/10.1056\/NEJMoa2309169","journal-title":"New England Journal of Medicine"},{"key":"10385_CR79","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s1470-2045(20)30180-7","volume":"21","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos, P. A., et al. (2020). Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: A multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, 21, 957\u2013968. https:\/\/doi.org\/10.1016\/s1470-2045(20)30180-7","journal-title":"Lancet Oncology"},{"key":"10385_CR80","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1038\/s41467-021-25904-w","volume":"12","author":"PA Konstantinopoulos","year":"2021","unstructured":"Konstantinopoulos, P. A., et al. (2021). A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer. Nat Commun, 12, 5574. https:\/\/doi.org\/10.1038\/s41467-021-25904-w","journal-title":"Nat Commun"},{"key":"10385_CR81","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","volume":"163","author":"PD Shah","year":"2021","unstructured":"Shah, P. D., et al. (2021). Combination ATR and PARP inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic Oncology, 163, 246\u2013253. https:\/\/doi.org\/10.1016\/j.ygyno.2021.08.024","journal-title":"Gynecologic Oncology"},{"key":"10385_CR82","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0140-6736(20)32554-x","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux, S., et al. (2021). Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet, 397, 281\u2013292. https:\/\/doi.org\/10.1016\/s0140-6736(20)32554-x","journal-title":"Lancet"},{"key":"10385_CR83","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.1158\/1078-0432.Ccr-20-0219","volume":"26","author":"AM Oza","year":"2020","unstructured":"Oza, A. M., et al. (2020). A biomarker-enriched, randomized phase II Trial of Adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Clin Cancer Res, 26, 4767\u20134776. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0219","journal-title":"Clin Cancer Res"},{"key":"10385_CR84","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/s41467-024-47215-6","volume":"15","author":"E Giudice","year":"2024","unstructured":"Giudice, E., et al. (2024). The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial. Nat Commun, 15, 2805. https:\/\/doi.org\/10.1038\/s41467-024-47215-6","journal-title":"Nat Commun"},{"key":"10385_CR85","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ygyno.2022.09.019","volume":"167","author":"PA Konstantinopoulos","year":"2022","unstructured":"Konstantinopoulos, P. A., et al. (2022). A phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer. Gynecologic Oncology, 167, 213\u2013225. https:\/\/doi.org\/10.1016\/j.ygyno.2022.09.019","journal-title":"Gynecologic Oncology"},{"key":"10385_CR86","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1200\/JCO.2021.39.15_suppl.3018","volume":"39","author":"MS Gordon","year":"2021","unstructured":"Gordon, M. S., et al. (2021). Phase 1b\/2a study of PLX2853, a small molecule BET inhibitor, in subjects with advanced solid tumors and lymphoma. Journal of Clinical Oncology, 39, 3018\u20133018. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.3018","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR87","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41580-021-00404-3","volume":"23","author":"HK Matthews","year":"2022","unstructured":"Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022). Cell cycle control in cancer. Nat Rev Mol Cell Biol, 23, 74\u201388. https:\/\/doi.org\/10.1038\/s41580-021-00404-3","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10385_CR88","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","volume":"78","author":"JM Cleary","year":"2020","unstructured":"Cleary, J. M., Aguirre, A. J., Shapiro, G. I., & D\u2019Andrea, A. D. (2020). Biomarker-guided development of DNA repair inhibitors. Mol Cell, 78, 1070\u20131085. https:\/\/doi.org\/10.1016\/j.molcel.2020.04.035","journal-title":"Mol Cell"},{"key":"10385_CR89","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nchembio.573","volume":"7","author":"PM Reaper","year":"2011","unstructured":"Reaper, P. M., et al. (2011). Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nature Chemical Biology, 7, 428\u2013430. https:\/\/doi.org\/10.1038\/nchembio.573","journal-title":"Nature Chemical Biology"},{"key":"10385_CR90","doi-asserted-by":"publisher","first-page":"100394","DOI":"10.1016\/j.xcrm.2021.100394","volume":"2","author":"H Xu","year":"2021","unstructured":"Xu, H., et al. (2021). CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Reports Medicine, 2, 100394. https:\/\/doi.org\/10.1016\/j.xcrm.2021.100394","journal-title":"Cell Reports Medicine"},{"key":"10385_CR91","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1200\/jco.22.00830","volume":"41","author":"S Fu","year":"2023","unstructured":"Fu, S., et al. (2023). Multicenter phase II trial of the WEE1 inhibitor adavosertib in refractory solid tumors harboring CCNE1 amplification. Journal of Clinical Oncology, 41, 1725\u20131734. https:\/\/doi.org\/10.1200\/jco.22.00830","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR92","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","volume":"17","author":"M Scaranti","year":"2020","unstructured":"Scaranti, M., Cojocaru, E., Banerjee, S., & Banerji, U. (2020). Exploiting the folate receptor \u03b1 in oncology. Nat Rev Clin Oncol, 17, 349\u2013359. https:\/\/doi.org\/10.1038\/s41571-020-0339-5","journal-title":"Nat Rev Clin Oncol"},{"key":"10385_CR93","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ygyno.2007.11.020","volume":"108","author":"KR Kalli","year":"2008","unstructured":"Kalli, K. R., et al. (2008). Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol, 108, 619\u2013626. https:\/\/doi.org\/10.1016\/j.ygyno.2007.11.020","journal-title":"Gynecol Oncol"},{"key":"10385_CR94","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1158\/1535-7163.Mct-14-1095","volume":"14","author":"O Ab","year":"2015","unstructured":"Ab, O., et al. (2015). IMGN853, a folate receptor-\u03b1 (FR\u03b1)-targeting antibody-drug conjugate, exhibits potent targeted antitumor activity against FR\u03b1-expressing tumors. Molecular Cancer Therapeutics, 14, 1605\u20131613. https:\/\/doi.org\/10.1158\/1535-7163.Mct-14-1095","journal-title":"Molecular Cancer Therapeutics"},{"key":"10385_CR95","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.neo.2016.11.002","volume":"18","author":"JF Ponte","year":"2016","unstructured":"Ponte, J. F., et al. (2016). Mirvetuximab Soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, potentiates the activity of standard of care therapeutics in ovarian cancer models. Neoplasia, 18, 775\u2013784. https:\/\/doi.org\/10.1016\/j.neo.2016.11.002","journal-title":"Neoplasia"},{"key":"10385_CR96","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1146\/annurev.immunol.20.091301.131133","volume":"20","author":"C Dong","year":"2002","unstructured":"Dong, C., Davis, R. J., & Flavell, R. A. (2002). MAP kinases in the immune response. Annu Rev Immunol, 20, 55\u201372. https:\/\/doi.org\/10.1146\/annurev.immunol.20.091301.131133","journal-title":"Annu Rev Immunol"},{"key":"10385_CR97","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/s1470-2045(05)70168-6","volume":"6","author":"JY Fang","year":"2005","unstructured":"Fang, J. Y., & Richardson, B. C. (2005). The MAPK signalling pathways and colorectal cancer. Lancet Oncol, 6, 322\u2013327. https:\/\/doi.org\/10.1016\/s1470-2045(05)70168-6","journal-title":"Lancet Oncol"},{"key":"10385_CR98","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie, H., Gagnon, J., & Therrien, M. (2020). ERK signalling: A master regulator of cell behaviour, life and fate. Nature Reviews Molecular Cell Biology, 21, 607\u2013632. https:\/\/doi.org\/10.1038\/s41580-020-0255-7","journal-title":"Nature Reviews Molecular Cell Biology"},{"key":"10385_CR99","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ygyno.2023.01.038","volume":"171","author":"CSE Hendrikse","year":"2023","unstructured":"Hendrikse, C. S. E., et al. (2023). The potential of RAS\/RAF\/MEK\/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis. Gynecologic Oncology, 171, 83\u201394. https:\/\/doi.org\/10.1016\/j.ygyno.2023.01.038","journal-title":"Gynecologic Oncology"},{"key":"10385_CR100","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/path.5545","volume":"253","author":"D Cheasley","year":"2021","unstructured":"Cheasley, D., et al. (2021). Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J Pathol, 253, 41\u201354. https:\/\/doi.org\/10.1002\/path.5545","journal-title":"J Pathol"},{"key":"10385_CR101","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ygyno.2025.06.022","volume":"200","author":"EH Stover","year":"2025","unstructured":"Stover, E. H., et al. (2025). The RAS-MEK-ERK pathway in low-grade serous ovarian cancer. Gynecol Oncol, 200, 22\u201332. https:\/\/doi.org\/10.1016\/j.ygyno.2025.06.022","journal-title":"Gynecol Oncol"},{"key":"10385_CR102","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","volume":"6","author":"L Huang","year":"2021","unstructured":"Huang, L., Guo, Z., Wang, F., & Fu, L. (2021). KRAS mutation: from undruggable to druggable in cancer. Signal Transduct Target Ther, 6, 386. https:\/\/doi.org\/10.1038\/s41392-021-00780-4","journal-title":"Signal Transduct Target Ther"},{"key":"10385_CR103","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A., et al. (2022). Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation. New England Journal of Medicine, 387, 120\u2013131. https:\/\/doi.org\/10.1056\/NEJMoa2204619","journal-title":"New England Journal of Medicine"},{"key":"10385_CR104","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan, K. K., et al. (2023). KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells. Cancer Cell, 41, 1606-1620.e1608. https:\/\/doi.org\/10.1016\/j.ccell.2023.07.002","journal-title":"Cancer Cell"},{"key":"10385_CR105","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/s1470-2045(12)70572-7","volume":"14","author":"J Farley","year":"2013","unstructured":"Farley, J., et al. (2013). Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: An open-label, single-arm, phase 2 study. Lancet Oncology, 14, 134\u2013140. https:\/\/doi.org\/10.1016\/s1470-2045(12)70572-7","journal-title":"Lancet Oncology"},{"key":"10385_CR106","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/jco.20.01164","volume":"38","author":"BJ Monk","year":"2020","unstructured":"Monk, B. J., et al. (2020). MILO\/ENGOT-ov11: Binimetinib versus physician\u2019s choice chemotherapy in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum. Journal of Clinical Oncology, 38, 3753\u20133762. https:\/\/doi.org\/10.1200\/jco.20.01164","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR107","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.1200\/JCO.2021.39.15_suppl.5519","volume":"39","author":"RN Grisham","year":"2021","unstructured":"Grisham, R. N., et al. (2021). Molecular results and potential biomarkers identified from MILO\/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC). Journal of Clinical Oncology, 39, 5519\u20135519. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.5519","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR108","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s0140-6736(21)02175-9","volume":"399","author":"DM Gershenson","year":"2022","unstructured":"Gershenson, D. M., et al. (2022). Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281\/LOGS): An international, randomised, open-label, multicentre, phase 2\/3 trial. Lancet, 399, 541\u2013553. https:\/\/doi.org\/10.1016\/s0140-6736(21)02175-9","journal-title":"Lancet"},{"key":"10385_CR109","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1200\/jco-25-00112","volume":"43","author":"SN Banerjee","year":"2025","unstructured":"Banerjee, S. N., et al. (2025). Efficacy and safety of Avutometinib \u00b1 Defactinib in recurrent low-grade serous ovarian cancer: primary analysis of ENGOT-OV60\/GOG-3052\/RAMP 201. J Clin Oncol, 43, 2782\u20132792. https:\/\/doi.org\/10.1200\/jco-25-00112","journal-title":"J Clin Oncol"},{"key":"10385_CR110","doi-asserted-by":"publisher","first-page":"101832","DOI":"10.1136\/ijgc-2024-005919","volume":"35","author":"R Grisham","year":"2025","unstructured":"Grisham, R., et al. (2025). GOG-3097\/ENGOT-ov81\/GTG-UK\/RAMP 301: A phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator\u2019s choice of treatment in patients with recurrent low grade serous ovarian cancer. International Journal of Gynecological Cancer, 35, 101832. https:\/\/doi.org\/10.1136\/ijgc-2024-005919","journal-title":"International Journal of Gynecological Cancer"},{"key":"10385_CR111","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.1200\/jco.2018.78.9990","volume":"36","author":"T Kaley","year":"2018","unstructured":"Kaley, T., et al. (2018). BRAF inhibition in BRAF(V600)-mutant gliomas: results from the VE-BASKET study. J Clin Oncol, 36, 3477\u20133484. https:\/\/doi.org\/10.1200\/jco.2018.78.9990","journal-title":"J Clin Oncol"},{"key":"10385_CR112","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1200\/jco-25-01348","volume":"44","author":"BM Slomovitz","year":"2026","unstructured":"Slomovitz, B. M., et al. (2026). Phase II trial of ribociclib plus letrozole in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum: A GOG partners trial (GOG 3026). Journal of Clinical Oncology, 44, 153\u2013163. https:\/\/doi.org\/10.1200\/jco-25-01348","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR113","doi-asserted-by":"publisher","first-page":"e000926","DOI":"10.1136\/esmoopen-2020-000926","volume":"5","author":"G Colon-Otero","year":"2020","unstructured":"Colon-Otero, G., et al. (2020). Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers. ESMO Open, 5, e000926. https:\/\/doi.org\/10.1136\/esmoopen-2020-000926","journal-title":"ESMO Open"},{"key":"10385_CR114","doi-asserted-by":"publisher","first-page":"TPS5603","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5603","volume":"39","author":"SN Banerjee","year":"2021","unstructured":"Banerjee, S. N., et al. (2021). ENGOT-ov60\/GOG3052\/RAMP 201: A phase 2 study of VS-6766 (dual RAF\/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC). Journal of Clinical Oncology, 39, TPS5603\u2013TPS5603. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS5603","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR115","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev-biochem-052521-040754","volume":"93","author":"H Jeon","year":"2024","unstructured":"Jeon, H., Tkacik, E., & Eck, M. J. (2024). Signaling from RAS to RAF: The molecules and their mechanisms. Annual Review of Biochemistry, 93, 289\u2013316. https:\/\/doi.org\/10.1146\/annurev-biochem-052521-040754","journal-title":"Annual Review of Biochemistry"},{"key":"10385_CR116","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1158\/2159-8290.Cd-24-0024","volume":"14","author":"R Yaeger","year":"2024","unstructured":"Yaeger, R., et al. (2024). A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation. Cancer Discovery, 14, 1599\u20131611. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0024","journal-title":"Cancer Discovery"},{"key":"10385_CR117","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1038\/nrm3629","volume":"14","author":"C Bertoli","year":"2013","unstructured":"Bertoli, C., Skotheim, J. M., & de Bruin, R. A. (2013). Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol, 14, 518\u2013528. https:\/\/doi.org\/10.1038\/nrm3629","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10385_CR118","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"T Otto","year":"2017","unstructured":"Otto, T., & Sicinski, P. (2017). Cell cycle proteins as promising targets in cancer therapy. Nature Reviews Cancer, 17, 93\u2013115. https:\/\/doi.org\/10.1038\/nrc.2016.138","journal-title":"Nature Reviews Cancer"},{"key":"10385_CR119","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R., et al. (2010). The landscape of somatic copy-number alteration across human cancers. Nature, 463, 899\u2013905. https:\/\/doi.org\/10.1038\/nature08822","journal-title":"Nature"},{"key":"10385_CR120","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41698-022-00288-2","volume":"6","author":"D Cheasley","year":"2022","unstructured":"Cheasley, D., et al. (2022). Molecular characterization of low-grade serous ovarian carcinoma identifies genomic aberrations according to hormone receptor expression. NPJ Precis Oncol, 6, 47. https:\/\/doi.org\/10.1038\/s41698-022-00288-2","journal-title":"NPJ Precis Oncol"},{"key":"10385_CR121","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/s1470-2045(13)70253-5","volume":"14","author":"W Sieh","year":"2013","unstructured":"Sieh, W., et al. (2013). Hormone-receptor expression and ovarian cancer survival: an ovarian tumor tissue analysis consortium study. Lancet Oncology, 14, 853\u2013862. https:\/\/doi.org\/10.1016\/s1470-2045(13)70253-5","journal-title":"Lancet Oncology"},{"key":"10385_CR122","first-page":"923","volume":"2","author":"R Hui","year":"1996","unstructured":"Hui, R., et al. (1996). Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clinical Cancer Research, 2, 923\u2013928.","journal-title":"Clinical Cancer Research"},{"key":"10385_CR123","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1096\/fj.14-262808","volume":"29","author":"L Mauro","year":"2015","unstructured":"Mauro, L., et al. (2015). Estrogen receptor-\u03b1 drives adiponectin effects on cyclin D1 expression in breast cancer cells. FASEB Journal, 29, 2150\u20132160. https:\/\/doi.org\/10.1096\/fj.14-262808","journal-title":"FASEB Journal"},{"key":"10385_CR124","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/jco.2016.71.0632","volume":"35","author":"DM Gershenson","year":"2017","unstructured":"Gershenson, D. M., et al. (2017). Hormonal Maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum. J Clin Oncol, 35, 1103\u20131111. https:\/\/doi.org\/10.1200\/jco.2016.71.0632","journal-title":"J Clin Oncol"},{"key":"10385_CR125","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s1470-2045(11)70404-1","volume":"13","author":"CL Pearce","year":"2012","unstructured":"Pearce, C. L., et al. (2012). Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol, 13, 385\u2013394. https:\/\/doi.org\/10.1016\/s1470-2045(11)70404-1","journal-title":"Lancet Oncol"},{"key":"10385_CR126","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","volume":"109","author":"JK Chan","year":"2008","unstructured":"Chan, J. K., et al. (2008). Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol, 109, 370\u2013376. https:\/\/doi.org\/10.1016\/j.ygyno.2008.02.006","journal-title":"Gynecol Oncol"},{"key":"10385_CR127","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1614814","volume":"376","author":"MS Anglesio","year":"2017","unstructured":"Anglesio, M. S., et al. (2017). Cancer-associated mutations in endometriosis without cancer. New England Journal of Medicine, 376, 1835\u20131848. https:\/\/doi.org\/10.1056\/NEJMoa1614814","journal-title":"New England Journal of Medicine"},{"key":"10385_CR128","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9, F., et al. (2019). Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. New England Journal of Medicine, 380, 1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904","journal-title":"New England Journal of Medicine"},{"key":"10385_CR129","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1158\/2159-8290.Cd-21-1696","volume":"12","author":"P Savas","year":"2022","unstructured":"Savas, P., et al. (2022). Alpelisib monotherapy for PI3K-Altered, pretreated advanced breast cancer: a phase II study. Cancer Discov, 12, 2058\u20132073. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-1696","journal-title":"Cancer Discov"},{"key":"10385_CR130","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","volume":"17","author":"P Mittal","year":"2020","unstructured":"Mittal, P., & Roberts, C. W. M. (2020). The SWI\/SNF complex in cancer - biology, biomarkers and therapy. Nature Reviews Clinical Oncology, 17, 435\u2013448. https:\/\/doi.org\/10.1038\/s41571-020-0357-3","journal-title":"Nature Reviews Clinical Oncology"},{"key":"10385_CR131","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1158\/1541-7786.Mcr-10-0398","volume":"8","author":"H Li","year":"2010","unstructured":"Li, H., Cai, Q., Godwin, A. K., & Zhang, R. (2010). Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Molecular Cancer Research, 8, 1610\u20131618. https:\/\/doi.org\/10.1158\/1541-7786.Mcr-10-0398","journal-title":"Molecular Cancer Research"},{"key":"10385_CR132","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nm.3799","volume":"21","author":"BG Bitler","year":"2015","unstructured":"Bitler, B. G., et al. (2015). Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nature Medicine, 21, 231\u2013238. https:\/\/doi.org\/10.1038\/nm.3799","journal-title":"Nature Medicine"},{"key":"10385_CR133","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1200\/JCO.2023.41.16_suppl.3094","volume":"41","author":"C Drescher","year":"2023","unstructured":"Drescher, C., et al. (2023). EZH2\/EZH1 inhibitor tulmimetostat (CPI-0209) in patients with advanced solid tumors or hematologic malignancies: Preliminary phase II results. Journal of Clinical Oncology, 41, 3094\u20133094. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.3094","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR134","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1200\/JCO.2025.43.16_suppl.3102","volume":"43","author":"LR Duska","year":"2025","unstructured":"Duska, L. R., et al. (2025). Phase II dose optimization update with EZH2\/EZH1 inhibitor tulmimetostat in patients with ARID1A-mutated ovarian clear cell carcinoma or endometrial carcinoma. Journal of Clinical Oncology, 43, 3102\u20133102. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3102","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR135","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1038\/s41591-024-02942-7","volume":"30","author":"CF Friedman","year":"2024","unstructured":"Friedman, C. F., et al. (2024). Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses. Nat Med, 30, 1330\u20131338. https:\/\/doi.org\/10.1038\/s41591-024-02942-7","journal-title":"Nat Med"},{"key":"10385_CR136","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaoncol.2025.1916","volume":"11","author":"B Gao","year":"2025","unstructured":"Gao, B., et al. (2025). Nivolumab and ipilimumab combination treatment in advanced ovarian and endometrial clear cell cancers: A nonrandomized clinical trial. JAMA Oncology, 11, 982\u2013989. https:\/\/doi.org\/10.1001\/jamaoncol.2025.1916","journal-title":"JAMA Oncology"},{"key":"10385_CR137","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","volume":"11","author":"R Kristeleit","year":"2025","unstructured":"Kristeleit, R., et al. (2025). Pembrolizumab in patients with advanced clear cell gynecological cancer: A phase 2 nonrandomized clinical trial. JAMA Oncology, 11, 377\u2013385. https:\/\/doi.org\/10.1001\/jamaoncol.2024.6797","journal-title":"JAMA Oncology"},{"key":"10385_CR138","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/s1470-2045(24)00437-6","volume":"25","author":"Z Peng","year":"2024","unstructured":"Peng, Z., et al. (2024). Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): A multicentre, single-arm, phase 2 trial. Lancet Oncology, 25, 1288\u20131297. https:\/\/doi.org\/10.1016\/s1470-2045(24)00437-6","journal-title":"Lancet Oncology"},{"key":"10385_CR139","doi-asserted-by":"publisher","first-page":"CT162","DOI":"10.1158\/1538-7445.Am2023-ct162","volume":"83","author":"YK Chae","year":"2023","unstructured":"Chae, Y. K., et al. (2023). Abstract CT162: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the clear cell ovarian, endometrial, cervical cancer cohorts. Cancer Research, 83, CT162\u2013CT162. https:\/\/doi.org\/10.1158\/1538-7445.Am2023-ct162","journal-title":"Cancer Research"},{"key":"10385_CR140","doi-asserted-by":"publisher","first-page":"LBA5500","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500","volume":"42","author":"DS Dizon","year":"2024","unstructured":"Dizon, D. S., et al. (2024). Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas. Journal of Clinical Oncology, 42, LBA5500\u2013LBA5500. https:\/\/doi.org\/10.1200\/JCO.2024.42.17_suppl.LBA5500","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR141","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1158\/1078-0432.Ccr-25-0201","volume":"31","author":"NYL Ngoi","year":"2025","unstructured":"Ngoi, N. Y. L., et al. (2025). Durvalumab versus physician\u2019s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA\/APGOT-OV2\/GCGS-OV3): A multicenter, randomized, phase 2 trial. Clinical Cancer Research, 31, 3907\u20133915. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-25-0201","journal-title":"Clinical Cancer Research"},{"key":"10385_CR142","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1093\/nar\/gkae233","volume":"52","author":"A Bakr","year":"2024","unstructured":"Bakr, A., et al. (2024). ARID1A regulates DNA repair through chromatin organization and its deficiency triggers DNA damage-mediated anti-tumor immune response. Nucleic Acids Research, 52, 5698\u20135719. https:\/\/doi.org\/10.1093\/nar\/gkae233","journal-title":"Nucleic Acids Research"},{"key":"10385_CR143","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1158\/1078-0432.Ccr-18-4222","volume":"25","author":"Y Park","year":"2019","unstructured":"Park, Y., et al. (2019). Loss of ARID1A in tumor cells renders selective vulnerability to combined ionizing radiation and PARP inhibitor therapy. Clinical Cancer Research, 25, 5584\u20135594. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-4222","journal-title":"Clinical Cancer Research"},{"key":"10385_CR144","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.Cd-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen, J., et al. (2015). ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov, 5, 752\u2013767. https:\/\/doi.org\/10.1158\/2159-8290.Cd-14-0849","journal-title":"Cancer Discov"},{"key":"10385_CR145","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1078-0432.Ccr-23-2409","volume":"30","author":"TA Yap","year":"2024","unstructured":"Yap, T. A., et al. (2024). First-in-human study of the ataxia telangiectasia and Rad3-Related (ATR) inhibitor Tuvusertib (M1774) as monotherapy in patients with solid tumors. Clin Cancer Res, 30, 2057\u20132067. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-2409","journal-title":"Clin Cancer Res"},{"key":"10385_CR146","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nrg1348","volume":"5","author":"H Ellegren","year":"2004","unstructured":"Ellegren, H. (2004). Microsatellites: simple sequences with complex evolution. Nature Reviews Genetics, 5, 435\u2013445. https:\/\/doi.org\/10.1038\/nrg1348","journal-title":"Nature Reviews Genetics"},{"key":"10385_CR147","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1146\/annurev.biochem.74.082803.133243","volume":"74","author":"TA Kunkel","year":"2005","unstructured":"Kunkel, T. A., & Erie, D. A. (2005). DNA mismatch repair. Annu Rev Biochem, 74, 681\u2013710. https:\/\/doi.org\/10.1146\/annurev.biochem.74.082803.133243","journal-title":"Annu Rev Biochem"},{"key":"10385_CR148","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.pharmthera.2018.04.004","volume":"189","author":"M Baretti","year":"2018","unstructured":"Baretti, M., & Le, D. T. (2018). DNA mismatch repair in cancer. Pharmacology & Therapeutics, 189, 45\u201362. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.04.004","journal-title":"Pharmacology & Therapeutics"},{"key":"10385_CR149","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.7150\/ijbs.71714","volume":"18","author":"Y He","year":"2022","unstructured":"He, Y., Zhang, L., Zhou, R., Wang, Y., & Chen, H. (2022). The role of DNA mismatch repair in immunotherapy of human cancer. International Journal of Biological Sciences, 18, 2821\u20132832. https:\/\/doi.org\/10.7150\/ijbs.71714","journal-title":"International Journal of Biological Sciences"},{"key":"10385_CR150","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/ijc.34165","volume":"151","author":"A Atwal","year":"2022","unstructured":"Atwal, A., et al. (2022). The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis. International Journal of Cancer, 151, 1626\u20131639. https:\/\/doi.org\/10.1002\/ijc.34165","journal-title":"International Journal of Cancer"},{"key":"10385_CR151","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ygyno.2022.03.016","volume":"165","author":"J Simil\u00e4-Maarala","year":"2022","unstructured":"Simil\u00e4-Maarala, J., et al. (2022). TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma. Gynecologic Oncology, 165, 577\u2013584. https:\/\/doi.org\/10.1016\/j.ygyno.2022.03.016","journal-title":"Gynecologic Oncology"},{"key":"10385_CR152","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/s1470-2045(22)00197-8","volume":"23","author":"LA Diaz Jr","year":"2022","unstructured":"Diaz, L. A., Jr., et al. (2022). Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol, 23, 659\u2013670. https:\/\/doi.org\/10.1016\/s1470-2045(22)00197-8","journal-title":"Lancet Oncol"},{"key":"10385_CR153","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/jco.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris, V. K., et al. (2023). Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol, 41, 678\u2013700. https:\/\/doi.org\/10.1200\/jco.22.01690","journal-title":"J Clin Oncol"},{"key":"10385_CR154","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.ccell.2025.05.010","volume":"43","author":"B Rousseau","year":"2025","unstructured":"Rousseau, B., et al. (2025). Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer. Cancer Cell, 43, 1313-1327.e1310. https:\/\/doi.org\/10.1016\/j.ccell.2025.05.010","journal-title":"Cancer Cell"},{"key":"10385_CR155","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2159-8290.Cd-21-1434","volume":"12","author":"G Crisafulli","year":"2022","unstructured":"Crisafulli, G., et al. (2022). Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. Cancer Discovery, 12, 1656\u20131675. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-1434","journal-title":"Cancer Discovery"},{"key":"10385_CR156","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/cncr.25460","volume":"117","author":"RJ Zaino","year":"2011","unstructured":"Zaino, R. J., et al. (2011). Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a gynecologic oncology group study. Cancer, 117, 554\u2013562. https:\/\/doi.org\/10.1002\/cncr.25460","journal-title":"Cancer"},{"key":"10385_CR157","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ygyno.2019.12.015","volume":"156","author":"KL Gorringe","year":"2020","unstructured":"Gorringe, K. L., et al. (2020). Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol, 156, 552\u2013560. https:\/\/doi.org\/10.1016\/j.ygyno.2019.12.015","journal-title":"Gynecol Oncol"},{"key":"10385_CR158","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/jco.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop, K., et al. (2012). BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 30, 2654\u20132663. https:\/\/doi.org\/10.1200\/jco.2011.39.8545","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR159","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/1471-2407-9-433","volume":"9","author":"JN McAlpine","year":"2009","unstructured":"McAlpine, J. N., et al. (2009). HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer, 9, 433. https:\/\/doi.org\/10.1186\/1471-2407-9-433","journal-title":"BMC Cancer"},{"key":"10385_CR160","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","volume":"26","author":"MM Moasser","year":"2007","unstructured":"Moasser, M. M. (2007). The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene, 26, 6469\u20136487. https:\/\/doi.org\/10.1038\/sj.onc.1210477","journal-title":"Oncogene"},{"key":"10385_CR161","unstructured":"ClinicalTrials.gov. Study of IBI354 versus investigator's choice of chemotherapy in patients with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer, <https:\/\/clinicaltrials.gov\/study\/NCT06834672> (2025)."},{"key":"10385_CR162","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.annonc.2022.08.001","volume":"33","author":"JE Augustin","year":"2022","unstructured":"Augustin, J. E., Soussan, P., & Bass, A. J. (2022). Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma. Ann Oncol, 33, 1134\u20131148. https:\/\/doi.org\/10.1016\/j.annonc.2022.08.001","journal-title":"Ann Oncol"},{"key":"10385_CR163","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/s1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain, S. M., et al. (2020). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncology, 21, 519\u2013530. https:\/\/doi.org\/10.1016\/s1470-2045(19)30863-0","journal-title":"Lancet Oncology"},{"key":"10385_CR164","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz, S. A., et al. (2018). Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol, 19, 115\u2013126. https:\/\/doi.org\/10.1016\/s1470-2045(17)30716-7","journal-title":"Lancet Oncol"},{"key":"10385_CR165","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/pgp.0000000000000530","volume":"38","author":"M K\u00f6bel","year":"2019","unstructured":"K\u00f6bel, M., et al. (2019). Ovarian carcinoma histotype: strengths and limitations of integrating morphology with immunohistochemical predictions. Int J Gynecol Pathol, 38, 353\u2013362. https:\/\/doi.org\/10.1097\/pgp.0000000000000530","journal-title":"Int J Gynecol Pathol"},{"key":"10385_CR166","doi-asserted-by":"publisher","unstructured":"K\u00f6bel, M. & Kang, E. Y. The evolution of ovarian carcinoma subclassification. Cancers (Basel) 14, https:\/\/doi.org\/10.3390\/cancers14020416 (2022).","DOI":"10.3390\/cancers14020416"},{"key":"10385_CR167","doi-asserted-by":"publisher","first-page":"288","DOI":"10.32074\/1591-951x-791","volume":"114","author":"C Fumagalli","year":"2022","unstructured":"Fumagalli, C., et al. (2022). In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD focus panel with Myriad myChoiceCDx assay. Pathologica, 114, 288\u2013294. https:\/\/doi.org\/10.32074\/1591-951x-791","journal-title":"Pathologica"},{"key":"10385_CR168","doi-asserted-by":"publisher","unstructured":"Heitz, F. et al. Implementing HRD testing in routine clinical practice on patients with primary high-grade advanced ovarian cancer. Cancers (Basel) 15, https:\/\/doi.org\/10.3390\/cancers15030818 (2023).","DOI":"10.3390\/cancers15030818"},{"key":"10385_CR169","doi-asserted-by":"publisher","first-page":"e70335","DOI":"10.1002\/cnr2.70335","volume":"8","author":"K Planisamy","year":"2025","unstructured":"Planisamy, K., et al. (2025). Routine tumor testing for homologous recombination deficiency in patients with high grade epithelial ovarian cancer at a statewide gynecological cancer service in Western Australia an observational study. Cancer Rep (Hoboken), 8, e70335. https:\/\/doi.org\/10.1002\/cnr2.70335","journal-title":"Cancer Rep (Hoboken)"},{"key":"10385_CR170","doi-asserted-by":"publisher","first-page":"100445","DOI":"10.1016\/j.modpat.2024.100445","volume":"37","author":"M Romey","year":"2024","unstructured":"Romey, M., et al. (2024). Systematic analysis of homologous recombination deficiency testing in ovarian cancer-development of recommendations for optimal assay performance. Modern Pathology, 37, 100445. https:\/\/doi.org\/10.1016\/j.modpat.2024.100445","journal-title":"Modern Pathology"},{"key":"10385_CR171","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1080\/14796694.2024.2433412","volume":"21","author":"A Hunt","year":"2025","unstructured":"Hunt, A., et al. (2025). Homologous recombination deficiency testing in patients with high grade ovarian cancer: Factors influencing test success. Future Oncology, 21, 341\u2013347. https:\/\/doi.org\/10.1080\/14796694.2024.2433412","journal-title":"Future Oncology"},{"key":"10385_CR172","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1200\/jco.19.02960","volume":"38","author":"PA Konstantinopoulos","year":"2020","unstructured":"Konstantinopoulos, P. A., et al. (2020). Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline. Journal of Clinical Oncology, 38, 1222\u20131245. https:\/\/doi.org\/10.1200\/jco.19.02960","journal-title":"Journal of Clinical Oncology"},{"key":"10385_CR173","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11864-024-01176-6","volume":"25","author":"R Ratnaparkhi","year":"2024","unstructured":"Ratnaparkhi, R., Javellana, M., Jewell, A., & Spoozak, L. (2024). Evaluation of homologous recombination deficiency in ovarian cancer. Current Treatment Options in Oncology, 25, 237\u2013260. https:\/\/doi.org\/10.1007\/s11864-024-01176-6","journal-title":"Current Treatment Options in Oncology"},{"key":"10385_CR174","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1136\/jcp-2023-208852","volume":"77","author":"F Pepe","year":"2024","unstructured":"Pepe, F., et al. (2024). In-house homologous recombination deficiency testing in ovarian cancer: A multi-institutional Italian pilot study. Journal of Clinical Pathology, 77, 478\u2013485. https:\/\/doi.org\/10.1136\/jcp-2023-208852","journal-title":"Journal of Clinical Pathology"},{"key":"10385_CR175","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","volume":"29","author":"J Mateo","year":"2018","unstructured":"Mateo, J., et al. (2018). A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO scale for clinical actionability of molecular targets (ESCAT). Annals of Oncology, 29, 1895\u20131902. https:\/\/doi.org\/10.1093\/annonc\/mdy263","journal-title":"Annals of Oncology"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10385-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10385-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-026-10385-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:02:56Z","timestamp":1792274576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-026-10385-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,17]]},"references-count":175,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10385"],"URL":"https:\/\/doi.org\/10.1007\/s10555-026-10385-4","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,17]]},"assertion":[{"value":"6 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"77"}}